Results 111 to 120 of about 2,758 (199)

Eculizumab or ravulizumab treatment effect in people with neuromyelitis optica spectrum disorder: a plain language summary of three studies

Journal of Comparative Effectiveness Research
What is this summary about? Neuromyelitis optica spectrum disorder (NMOSD for short) is a rare autoimmune health condition, meaning that the body’s natural defense system (the immune system) attacks the body’s own tissues.
Alfredo Damasceno, Mariano Marrodan
doaj   +1 more source

Efficacy of Ravulizumab During the Acute Phase of Neuromyelitis Optica Spectrum Disorder. [PDF]

Case Rep Neurol Med
Tsuzaki K, Mitsui G, Inagaki Y, Uehara N, Wada S, Hamano T.   +5 more
europepmc   +1 more source

Neuromyelitis Optica Spectrum Disorder in a Pediatric Patient: Literature Review with Case Report [PDF]

Introduction: Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune astrocytopathy of the central nervous system (CNS) with secondary demyelination, often associated with the anti-aquaporin-4 (anti-AQP4) antibody.
de Almeida, Zenon Ferreira, de Freitas, Juliana Pastana Ramos, De Souza da Nóbrega, Rebeca   +2 more
core   +1 more source

VFC resolution update : meningococcal vaccines [PDF]

Mening-04-Whitlatch-508 ...

core  

Epidemiology and care management of Paroxysmal Nocturnal Hemoglobinuria (PNH) in a real-world setting in France: Description from the French National Hospitalization Database. [PDF]

PLoS One
Peffault de Latour R, Pibre S, Vercruyssen J, Desjuzeur-Bellais ML, Pau D, Bénard S, Chillotti L, Grandfils N.   +7 more
europepmc   +1 more source

The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference [PDF]

Uncontrolled complement activation can cause or contribute to glomerular injury in multiple kidney diseases. Although complement activation plays a causal role in atypical hemolytic uremic syndrome and C3 glomerulopathy, over the past decade, a rapidly ...
Barratt, Jonathan, Beck Jr, Laurence H, Cheung, Michael, Fakhouri, Fadi, Gale, Daniel P, Goicoechea de Jorge, Elena, Jadoul, Michel, King, Jennifer M, Mosca, Marta, Noris, Marina, Pickering, Matthew C, Smith, Richard JH, Susztak, Katalin, Thurman, Joshua M, Vivarelli, Marina, Winkelmayer, Wolfgang C   +15 more
core  

Safety and efficacy of ravulizumab in patients with NMOSD previously treated with rituximab: A post hoc analysis of the CHAMPION-NMOSD trial. [PDF]

Mult Scler
Bennett JL, Bhattacharyya S, Zabeti A, Levy M, de Sèze J, Taney MJ, Parks B, Allen K, Akpoji U, Pittock SJ.   +9 more
europepmc   +1 more source

Comparative Efficacy of Complement Inhibitors in Complement Inhibitor-Naïve PNH: A Systematic Review With Supportive Exploratory Network Meta-Analysis of Randomized Trials. [PDF]

EJHaem
Ishaque R, Talpur AS, Sidra H, Memon H, Memon FT, Talat F, Rafiq T, Rayamajhi S.   +7 more
europepmc   +1 more source

Complement C5 inhibition with eculizumab or ravulizumab is associated with increased cardiovascular and thromboembolic risk after ST-elevation myocardial infarction: a propensity-matched global retrospective cohort study. [PDF]

BMC Cardiovasc Disord
Vahldieck C.
europepmc   +1 more source

Ravulizumab-Cwvz (Ultomiris®)

Oncology Times, 2019
openaire   +2 more sources